News: $NVTA Invitae Announces Program with BioMarin to Expand Access to Genetic Testing for Skeletal Dysplasias
SAN FRANCISCO , Dec. 10, 2019 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of Discover Dysplasias™ , an initiative with BioMarin Pharmaceutical to offer genetic testing at no charge to patients who show signs or symp...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.